Spruce Biosciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SPRB research report →
Companywww.sprucebiosciences.com
Spruce Biosciences, Inc. , a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial.
- CEO
- Javier Szwarcberg
- IPO
- 2020
- Employees
- 20
- HQ
- Daly City, CA, US
Price Chart
Valuation
- Market Cap
- $71.02M
- P/E
- -1.91
- P/S
- 0.00
- P/B
- 2.05
- EV/EBITDA
- -0.65
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -155.40%
- ROIC
- -74.40%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-38,966,000 · 26.53%
- EPS
- $-50.83 · 47.46%
- Op Income
- $-36,513,000
- FCF YoY
- 40.45%
Performance & Tape
- 52W High
- $838.13
- 52W Low
- $7.00
- 50D MA
- $60.66
- 200D MA
- $70.66
- Beta
- 3.31
- Avg Volume
- 59.50K
Get TickerSpark's AI analysis on SPRB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 9, 26 | Hooks Corwin Dale | other | 11,000 |
| Mar 9, 26 | Hooks Corwin Dale | other | 0 |
| Dec 11, 25 | Ways Douglas Kirk | other | 5,000 |
| Dec 11, 25 | Ways Douglas Kirk | other | 1,250 |
| Dec 11, 25 | Ways Douglas Kirk | other | 1,250 |
| Dec 11, 25 | Ways Douglas Kirk | other | 400 |
| Dec 11, 25 | Ways Douglas Kirk | other | 266 |
| Dec 11, 25 | Ways Douglas Kirk | sell | 266 |
| Dec 11, 25 | Ways Douglas Kirk | sell | 400 |
| Dec 31, 25 | Szwarcberg Javier B. | other | 4,690 |
Our SPRB Coverage
We haven't published any research on SPRB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SPRB Report →